SCIENCE MEDICINES HEALTH
EPAR summary for the public
This is a summary of the European public assessment report (EPAR) for Brimica Genuair. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Brimica Genuair.
For practical information about using Brimica Genuair, patients should read the package leaflet or contact their doctor or pharmacist.
Brimica Genuair is a medicine used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Brimica Genuair is used for maintenance (regular) treatment.
Brimica Genuair contains two active substances: aclidinium bromide and formoterol fumarate dihydrate.
Brimica Genuair is available as an inhalation powder in a portable inhaler device. The inhaler delivers 340 micrograms of aclidinium and 12 micrograms of formoterol fumarate dihydrate for each inhalation. The recommended dose of Brimica Genuair is one inhalation twice a day. For detailed information on how to use the inhaler correctly, see the instructions in the package leaflet.
Brimica Genuair can only be obtained with a prescription.
An agency of the European Union
30 Churchill Place • Canary Wharf • London E14 5EU • United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact
© European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged.
The two active substances in Brimica Genuair, aclinidium bromide and formoterol fumarate dihydrate, work by keeping the airways open and allowing the patient to breathe more easily.
Aclidinium bromide is a long-acting muscarinic antagonist. This means that it widens the airways by blocking some receptors in muscle cells in the lungs called muscarinic (also known as cholinergic) receptors, which control the contraction of muscles. When aclidinium bromide is inhaled, it causes the muscles of the airways to relax, helping to keep the airways open and allowing the patient to breathe more easily.
Formoterol is a long-acting beta-2 agonist. It works by attaching to receptors known as beta-2 receptors found in the muscles of the airways. When it attaches to these receptors, it causes the muscles to relax, which keeps the airways open and helps with the patient's breathing.
Long-acting muscarinic antagonists and long-acting beta-2 agonists are commonly combined in the management of COPD. Aclidinium bromide has been authorised in the EU as Bretaris Genuair and Eklira Genuair since July 2012; formoterol has been marketed in the EU since the 1990s.
Brimica Genuair has been studied in 2 main studies involving over 3,400 patients with COPD, in which it was compared with aclidinium alone, formoterol alone and placebo (a dummy treatment). The main measure of effectiveness was based on changes in patients' forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after six months.
Results showed that, after six months of treatment, the increase in FEV1 (measured one hour after an inhalation) was 293 milliliters (ml) more with Brimica Genuair than with placebo and 118 ml more with Brimica Genuair than with aclidinium alone. However the improvement over formoterol alone was small and not considered clinically significant: FEV1 measured in the morning before the inhalation was 68 ml more with Brimica Genuair than with formoterol alone. Brimica Genuair was also shown to increase the percentage of patients who had an improvement in breathlessness compared with placebo.
Side effects with Brimica Genuair are similar to those with the individual components. The most common side effects (seen in around 7 patients in 100) are nasopharyngitis (inflammation of the nose and throat) and headache.
For the full list of all side effects and restrictions with Brimica Genuair, see the package leaflet.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Brimica Genuair's benefits are greater than its risks and recommended that it be approved for use in the EU. The CHMP noted that Brimica Genuair was shown to significantly improve lung function in patients with COPD compared with placebo, although the improvement observed when Brimica Genuair was compared with one of the components on its own, formoterol, was small.
Regarding safety, the number of side effects reported with Brimica Genuair was low and did not raise any major safety concern. In addition, the safety profile of the two components is well known, and there is no evidence that the combination is worse than the individual components.
A risk management plan has been developed to ensure that Brimica Genuair is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Brimica Genuair, including the appropriate precautions to be followed by healthcare professionals and patients.
In addition, as long-acting muscarinic antagonists may have an effect on the heart and blood vessels, the company that markets Brimica Genuair will provide the results of studies to further evaluate the cardiovascular safety of the medicine.
The European Commission granted a marketing authorisation valid throughout the European Union for Brimica Genuair on 19 November 2014.
The full EPAR and risk management plan summary for Brimica Genuair can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. For more information about treatment with Brimica Genuair, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
This summary was last updated in 11-2014.